



Rebiotix Media Contact:
Jason Rando
Tiberend Strategic Advisors
212-375-2665
jrando@tiberend.com

**Rebiotix Microbiota Restoration Therapy™ Products, Microbiome Health Index™ to
Take Center Stage at Digestive Disease Week 2018**

*Interim analysis of RBX7455 Oral Formulation Phase 1 study, RBX2660 controlled trial
outcomes and expansion of Microbiome Health Index™ to be featured in podium, poster
presentations*

ROSEVILLE, MN – June 4, 2018 – [Rebiotix Inc.](#) announced today that data analyses from clinical studies of the company's first two [Microbiota Restoration Therapy™](#) products, [RBX7455](#) and [RBX2660](#), as well as ongoing [Microbiome Health Index™](#) research, will be presented in two podium presentations and one poster presentation during the [Digestive Disease Week 2018](#) (DDW2018) meeting to be held June 2-5 in Washington, D.C. The data to be presented will provide additional critical evidence in the development of the company's MRT products currently intended to treat patients suffering from recurrent *Clostridium difficile* infection (rCDI).

The schedule of presentations at DDW2018 is as follows:

- Podium Presentation:** *The Microbiota-based Drug RBX2660 is Efficacious and Safe in Patients with Recurrent Clostridium difficile Infections: Results from 2 Controlled Clinical Trials*
E. Dubberke, P. Plumb, R. Orenstein, S. Khanna, G. Hecht, H. DuPont, C. Lee, D. Gerding
- Day & Time:** Tuesday, June 5, 2:45-3:00 pm EDT
- Session & Location:** 146A; 4485 Clinical Practice, Healthcare Delivery and Disparities
- Poster Talk:** *A Lyophilized, Non-frozen, Oral Microbiota-based Drug RBX7455 is Safe, Reduces Clostridium difficile Infection Recurrence, and Restores the Microbiome*
- Investigators:** S. Khanna, D. Pardi, D. Gerding, K. Blount, C. Jones, B. Shannon, E. Deych
- Day & Time:** Tuesday, June 5, 12:00-2:00 pm EDT



Session & Location: Tu1883 Clinical Track, Microbiome in Gastrointestinal and Liver Disease

Poster Talk: *Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Continued Evaluation of a Prototype Microbiome Health Index™*

Investigators: K. Blount, C. Jones, B. Shannon, E. Deych

Day & Time: Tuesday, June 5 12:00-2:00 pm EDT

Session & Location: Tu1872 Clinical Track, Microbiome in Gastrointestinal and Liver Disease

About Rebiotix Inc.

Rebiotix Inc., which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and [diverse clinical pipeline](#), with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent *Clostridium difficile* (*C. diff*) infection. RBX2660 has been granted [Fast Track status](#), Orphan Drug and [Breakthrough Therapy designation from the FDA](#) for its potential to prevent recurrent *C. diff* infection. Rebiotix's clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently the subject of an [investigator-sponsored Phase 1 trial for the prevention of recurrent *C. diff* infection](#). In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering [Microbiota Restoration Therapy™ platform](#). The MRT™ platform is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient's intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women's health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company's research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com.